These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. The impact of response on bone-directed therapy in patients with multiple myeloma. Larocca A; Child JA; Cook G; Jackson GH; Russell N; Szubert A; Gregory WM; Brioli A; Owen RG; Drayson MT; Wu P; Palumbo A; Boccadoro M; Davies FE; Morgan GJ Blood; 2013 Oct; 122(17):2974-7. PubMed ID: 23974194 [TBL] [Abstract][Full Text] [Related]
44. Clinical trials of bisphosphonates in multiple myeloma. Mahindra A; Pozzi S; Raje N Clin Adv Hematol Oncol; 2012 Sep; 10(9):582-7. PubMed ID: 23073123 [TBL] [Abstract][Full Text] [Related]
45. Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. Lee OL; Horvath N; Lee C; Joshua D; Ho J; Szer J; Quach H; Spencer A; Harrison S; Mollee P; Roberts AW; Talaulikar D; Brown R; Augustson B; Ling S; Jaksic W; Gibson J; Kalff A; Johnston A; Kalro A; Ward C; Prince HM; Zannettino A Intern Med J; 2017 Aug; 47(8):938-951. PubMed ID: 28782211 [TBL] [Abstract][Full Text] [Related]
46. Bisphosphonates for cancer patients: why, how, and when? Body JJ; Mancini I Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223 [TBL] [Abstract][Full Text] [Related]
47. Mechanisms of bone destruction in multiple myeloma. Terpos E; Christoulas D; Gavriatopoulou M; Dimopoulos MA Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28940410 [TBL] [Abstract][Full Text] [Related]
48. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. Cetiner S; Sucak GT; Kahraman SA; Aki SZ; Kocakahyaoglu B; Gultekin SE; Cetiner M; Haznedar R J Bone Miner Metab; 2009; 27(4):435-43. PubMed ID: 19240969 [TBL] [Abstract][Full Text] [Related]
49. Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis. Lopez-Olivo MA; Shah NA; Pratt G; Risser JM; Symanski E; Suarez-Almazor ME Support Care Cancer; 2012 Nov; 20(11):2985-98. PubMed ID: 22956190 [TBL] [Abstract][Full Text] [Related]
50. Aetiology of bone disease and the role of bisphosphonates in multiple myeloma. Ashcroft AJ; Davies FE; Morgan GJ Lancet Oncol; 2003 May; 4(5):284-92. PubMed ID: 12732166 [TBL] [Abstract][Full Text] [Related]
51. Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective. Delea TE; Rotter J; Taylor M; Chandiwana D; Bains M; El Ouagari K; Kaura S; Morgan GJ J Med Econ; 2012; 15(3):454-64. PubMed ID: 22316275 [TBL] [Abstract][Full Text] [Related]
52. Novel therapeutic targets in myeloma bone disease. Webb SL; Edwards CM Br J Pharmacol; 2014 Aug; 171(16):3765-76. PubMed ID: 24750110 [TBL] [Abstract][Full Text] [Related]
53. The role of bisphosphonates in breast cancer. Theriault RL J Natl Compr Canc Netw; 2003 Apr; 1(2):232-41. PubMed ID: 19768882 [TBL] [Abstract][Full Text] [Related]
54. Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma. Tan M; Kalin-Hajdu E; Narayan R; Wong SW; Martin TG J Oncol Pharm Pract; 2019 Jul; 25(5):1253-1257. PubMed ID: 30005587 [TBL] [Abstract][Full Text] [Related]
55. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303 [TBL] [Abstract][Full Text] [Related]
56. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Terpos E; Berenson J; Cook RJ; Lipton A; Coleman RE Leukemia; 2010 May; 24(5):1043-9. PubMed ID: 20376081 [TBL] [Abstract][Full Text] [Related]
57. Advances in imaging and the management of myeloma bone disease. Terpos E; Moulopoulos LA; Dimopoulos MA J Clin Oncol; 2011 May; 29(14):1907-15. PubMed ID: 21483016 [TBL] [Abstract][Full Text] [Related]
59. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer. Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085 [TBL] [Abstract][Full Text] [Related]
60. Further analyses of the Myeloma IX Study. Morgan GJ Lancet; 2011 Aug; 378(9793):768-9. PubMed ID: 21872746 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]